Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Iolanda Conde Fernandes
Centro Hospitalar do Porto, EPE – Hospital de Santo António,
Building the External Consultations - Former CICAP, Rua D. Manuel II, s / n, 4099-001 Porto
Portugal
Rapid Communication
Effectiveness of Aprepitant in Patients with Refractory Pruritus Secondary to Sézary Syndrome
Author(s): Iolanda Conde Fernandes, Tiago Torres, Manuela Selores, Rosário Alves and Margarida LimaIolanda Conde Fernandes, Tiago Torres, Manuela Selores, Rosário Alves and Margarida Lima
Background: In advanced stages, patients with Sézary Syndrome (SS) commonly report an ill-defined, severe and diffuse pruritus. Recently, it has been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) antagonist, may have an important role in relief of refractory pruritus in patients with SS.
Material and methods: A prospective study which included four patients with SS, in whom pruritus is the main symptom, was performed. Our purpose was to assess efficacy of Aprepitant for treatment of refractory pruritus, secondary to SS. Patients were treated with Aprepitant 80 mg/d during 10 days and then the dosage was reduced to alternate days. The length of treatment ranged between 4 and 23 weeks. Improvement was assessed by the Dermatology Life Quality Index (DLQI) questionnaire, which ranges from 0 to 30, with high scores indicating .. View More»
DOI:
10.4172/2155-9554.1000149